Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 9Phase 3 5Phase 1/2 3Phase NA 2Phase 4 2Phase 2/3 1

Status

Active not recruiting 3Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5Gastrointestinal 5

Conditions

Breast Neoplasms 250Carcinoma, Non-Small-Cell Lung 226Prostatic Neoplasms 118Neoplasms 106Multiple Myeloma 91Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 67Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 48Melanoma 47Carcinoma, Renal Cell 45Leukemia, Lymphocytic, Chronic, B-Cell 44Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Recurrence 41Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Nasopharyngeal Carcinoma 34Lymphoma, Follicular 34Head and Neck Neoplasms 34Pancreatic Neoplasms 32Rectal Neoplasms 31Lymphoma, Large B-Cell, Diffuse 30Endometrial Neoplasms 29

Interventions

Sunitinib 4ripretinib 2Midazolam 1Imatinib Mesylate 1IDRX-42 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Stromal Tumors × 1 year × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Phase 3 Active not recruiting
482 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT07585266 2026-05-13

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

GlaxoSmithKline

Phase 3 Not yet recruiting
800 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03673501 2026-02-05

INTRIGUE

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
453 enrolled 20 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05734105 2025-12-17

INSIGHT

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
54 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡